Original research paper

Medicarpin suppresses lung cancer cell growth *in vitro* and *in vivo* by inducing cell apoptosis

ZONGYI SHEN[1,a]
LIQI YIN[1,a]
MANXIA CHANG[1]
HAIFENG WANG[2]
MINGXUAN HAO[1]
YOUFENG LIANG[1]
RUI GUO[1]
YING BI[1]
JIANSONG WANG[2]
CHANGYUAN YU[1]
JINMEI LI[3,4]
QIONGLI ZHAI[5]
RUNFEN CHENG[5]
JINKU ZHANG[3,4]
JIRUI SUN[3,4,*] ID
ZHAO YANG[1,6,*] ID

[1] *College of Life Science and Technology, Innovation Center of Molecular Diagnostics, Beijing University of Chemical Technology, Beijing 100029, China*

[2] *Department of Urology, The Second Affiliated Hospital of Kunming Medical University, Kunming 650101, China*

[3] *Department of Pathology, Baoding No. 1 Central Hospital, Baoding 071000, Hebei, China*

[4] *Key Laboratory of Molecular Pathology and Early Diagnosis of Tumor in Hebei Province, Baoding 071000, Hebei, China*

[5] *Department of Pathology, National Clinical Research Center of Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, China*

[6] *College of Life Science and Technology, Key Laboratory of Protection and Utilization of Biological Resources in Tarim Basin of Xinjiang Production and Construction Corps, Tarim University, Alar 843300 Xinjiang, China*

* Correspondence; e-mail: yangzhao@mail.buct.edu.cn; sjr75111863@sina.com
[a] These authors have contributed equally to this work.

ABSTRACT

Lung cancer (LC) is the leading cause of cancer deaths worldwide. Surgery, chemoradiotherapy, targeted therapy, and immunotherapy are considered dominant treatment strategies for LC in the clinic. However, drug resistance and metastasis are two major challenges in cancer therapies. Medicarpin (MED) is an isoflavone compound isolated from alfalfa, which is usually used in traditional medicine. This study was designed to evaluate the anti-LC effect and reveal the underlying mechanisms of MED *in vivo* and *in vitro*. We found that MED could significantly inhibit proliferation, induce apoptosis, and cell cycle arrest of A549 and H157 cell lines. Basically, MED induced cell apoptosis of LC cells by upregulating the expression of pro-apoptotic proteins BAX and Bak1, leading to the cleavage of caspase-3 (Casp3). Moreover, MED inhibited the proliferation of LC cells *via* downregulating the expression of proliferative protein Bid. Overall, MED inhibited LC cell growth *in vitro* and *in vivo via* suppressing cell proliferation and inducing cell apoptosis, suggesting the therapeutic potential of MED in treating LC.

Keywords: lung cancer, medicarpin, cell apoptosis, cell cycle arrest

Lung cancer (LC) is the most common primary malignant tumor worldwide and the rates of incidence and mortality of LC are increasing every year. About 2.2 million new cases of LC occurred and 1.7 million deaths resulted from LC worldwide in 2020, which was the highest among all types of cancer (1). In the clinic, LC is divided into small cell lung carcinoma (SCLC) and non-small cell lung carcinoma (NSCLC), in which NSCLC and SCLC account for 85 and 15 % of all LC cases, resp. (2).

The treatment approaches of LC patients include surgery, chemotherapy, targeted therapy, immunotherapy, *etc*. Chemotherapeutic drugs are widely applied in the treatment of LC (3). However, chemotherapy often leads to adverse effects in LC patients, such as vomiting and diarrhea. By targeting specific variations of genes and proteins of cancer cells, targeted therapy presents better therapeutic effects, nearly without side effects. For example, gefitinib (an epidermal growth factor receptor tyrosine kinase inhibitor, EGFR-TKIs) prolonged the median progression-free survival (PFS) of NSCLC patients with EGFR mutations from 5.4 months to 10.8 months and reduced the incidence of severe toxic effects from 71.7 to 41.2 % compared to chemotherapy (4, 5). Additionally, checkpoint inhibitor--based immunotherapy could prolong the median PFS of NSCLC patients with high expression of PD-L1 from 6.0 months to 10.3 months (6). However, targeted therapy and immunotherapy were only effective for part of LC patients, and all of the patients receiving TKIs became drug-resistant. It is urgent to develop novel anti-LC drugs and reveal the underlying molecular mechanisms.

Recent studies showed that some natural compounds extracted from natural herbs, such as ligustilide, polydatin, 6-gingerol, and tanshinone IIA, exhibited antitumor activity against different kinds of cancer (7). In addition, numerous natural compounds could enhance the immune function of the body, reverse multi-drug resistance, as well as prolong the overall survival (OS) of cancer patients (8). For example, etoposide is a semi-synthetic derivative of podophyllotoxin, a non-alkaloid lignin isolated from the roots and rhizomes of *Podophyllum peltatum* (9). In a phase III trial, the median OS of 95 patients with stage III NSCLC treated with etoposide plus cisplatin reached 23.3 months (10). Another phase III trial has shown that albumin-bound paclitaxel nanoparticles could prolong the median OS of patients with NSCLC to 16.2 months compared with the docetaxel group (13.6 months) (11). In the preclinical stage, some natural compounds also exhibited anti-tumor effects against LC. For instance, ligustilide extracted from traditional Chinese herbs *Angelica sinensis* and *Ligusticum chuanxiong*, could significantly inhibit proliferation and induce apoptosis of human NSCLC cell lines A549 and H1299 *in vitro* and *in vivo* (12). Additionally, polydatin extracted from the perennial herb *Polygonum cuspidatum*, could suppress the proliferation of NSCLC cells by inhibiting the activation of NLRP3 inflammasome *via* the NF-κB pathway (13).

Current therapeutic strategies among natural compounds focus on the suppression of tumorigenesis and progression *via* modulating multiple signaling pathways to induce apoptosis, arrest the cell cycle, and inhibit angiogenesis and invasion (14). Apoptosis is a highly regulated process of cell death triggered by various endogenous or exogenous stimuli, which is essential in development, homeostasis, and aging. For instance, sanguinarine induced apoptosis *via* downregulation of the constitutively active JAK/STAT pathway in NCI-H-1975 and HCC-827 NSCLC cell lines (15). The other natural compounds lanatoside C, tubeimoside-1, lotus leaf flavonoids, and ebractenoid F are also found to exhibit antitumor activity in LC (Table I).

Table I. Application of natural compounds in tumor treatment

Compound	Cancer type	Research object(s)	Inhibitory effect IC_{50}	Mechanism(s)	Ref.
	Head and neck squamous cell carcinoma	SCCL-MT1 cells	80 µmol L^{-1} (48 h)	Activation of PI3K/AKT signaling pathway by increasing the expression of *PTEN* gene	22
	Leukemia	Drug-sensitive P388 cells	90 µmol L^{-1}	Activation of mitochondrial apoptotic pathway by upregulating pro-apoptotic proteins (BAX) and downregulating anti-apoptotic proteins (Bcl-2)	20
		Multidrug-resistant P388 leukemia cells	90 µmol L^{-1}		
Medicarpin		K562, LAMA-84 U937 and OCIAML-3	Not specified	Activation of ROS-JNK-CHOP pathway and apoptosis by upregulating DR5	21
	Bladder cancer	EJ-1	79.1 µmol L^{-1} (24 h)	Activation of mitochondrial apoptotic pathway by upregulating Bak1, Bcl2-L-11 and Casp3 proteins	16
		T24	80.3 µmol L^{-1} (24 h)		
	Lung cancer	A549	290.8 ± 23.2 µmol L^{-1} (24 h) 206.8 ± 13.2 µmol L^{-1} (48 h)	Activation of mitochondrial apoptotic pathway by upregulating pro-apoptotic proteins (BAX, Bak1 and Casp3) and downregulating anti-apoptotic proteins (Bcl-2)	This study
		H157	125.5 ± 9.2 µmol L^{-1} (24 h) 102.7 ± 13.2 µmol L^{-1} (48 h)		
Sanguinarine	Lung cancer	NCI-H-1975	0.92 µmol L^{-1} (24 h)	1. Release of cytochrome c accompanied by caspase activation 2. Production of reactive oxygen species 3. Suppression of JAK/STAT pathway by STAT3 silencing	15
		HCC-827	0.898 µmol L^{-1} (24 h)		
	Normal lung cells	LL24	4.36 µmol L^{-1} (24 h)		

Compound		Cell line	Concentration	Mechanism	Ref.
Lanatoside C		A549	56.49 ± 5.3 nmol L⁻¹ (24 h)	1. Inhibition of cell proliferation and induction of apoptosis 2. Blocking MAPK/Wnt/PAM signaling pathways by inducing cell cycle arrest at G2/M phase 3. Inhibition of PI3K/AKT/mTOR signaling pathways by downregulating AKT, mTOR, LC3 and PI3K	31
Tubeimoside-1	Lung cancer	A549	12.3 µmol L⁻¹ (24 h)	Activation of MAPK-JNK signaling pathway by upregulating cell cycle genes *p15, p21* and *cyclin-B1*	32
		PC9	10.2 µmol L⁻¹ (24 h)		
Lotus leaf flavonoids		A549	282.1 ± 9.63 µg mL⁻¹	Induction of apoptosis by upregulating p38 MAPK, Casp3, Casp9, Cleaved Casp3, Cleaved Casp9 and BAX, as well as downregulating Bcl-2, Cu/Zn-SOD, CAT, Nrf2, NQO1 and HO-1	33
		H446	292.9 ± 11.22 µg mL⁻¹		
Ebractenoid F		A549	38 µmol L⁻¹ (72 h)	1. Targeting CHI3L1 and blocking AKT signal 2. Cell cycle arrest by decreasing CDK2, CDK3, CDK4, CDK6, Cyclin C and cyclin D1	40
		H460	38 µmol L⁻¹ (72 h)		

Medicarpin (MED) is an isoflavone compound isolated from alfalfa (16), which is usually used in traditional medicine. Its molecular formula is $C_{16}H_{14}O_4$ (Fig. 1) (17). Recent studies reported that MED contributed to bone sparing effect in ovariectomized mice *via* stimulation of osteoblast differentiation (18) and inhibition of osteoclastogenesis (19). Importantly, MED presented antitumor activity. For instance, MED-induced cell apoptosis of the doxorubicin-resistant P388 leukemia cells, which is a monocyte/macrophage-like cell line derived from mouse lymphoma (20). Furthermore, MED sensitized myeloid leukemia cells K562 and U937 to tumor necrosis factor α-related apoptosis (21). In addition, MED could upregulate *AKT* and tumor-suppressor gene *PTEN* to activate the PI3K/AKT signaling pathway in head and neck squamous cell carcinoma (22). Although the natural biological function of MED was identified in bone formation, the therapeutic effects of MED on LC and the underlying antitumor mechanisms remain obscure. The purpose of this study is to determine whether MED exerts antitumor activity in lung cancer and investigate the potential antitumor mechanisms of MED in LC.

EXPERIMENTAL

Cell culture and reagents

A549 and H157 LC cell lines, which were obtained from Procell Life Science & Technology Co., Ltd. (China) were cultured in RPMI-1640 medium (HyClone, USA) con-

Fig. 1. Chemical structure of medicarpin.

taining 10 % fetal bovine serum (Gibco, USA), 1 % penicillin-streptomycin (Gibco), which was maintained at 37 °C in 5 % CO_2 environment.

Medicarpin was purchased from Desite Biotechnology Co., Ltd. (China, purity of ≥ 98.0 %). Medicarpin (2.7 mg) was dissolved in 200 µL dimethyl sulfoxide (DMSO) to obtain the stock solution (50 mmol L^{-1}) and stored at –20 °C.

Cell counting kit-8 assay

Cells were resuspended and cultured into 96-well culture plates at a density of 5,000 cells per well. The stock solution (50 mmol L^{-1}) was diluted 100, 200, 400, 800, and 1600 times with RPMI-1640; cells were incubated with various concentrations of MED for 24 or 48 h. Cell viability was analyzed by cell counting kit-8 (CCK8, Beyotime, China) with DMSO as a control sample.

Cell cycle assay

A549 and H157 cells were cultured in 6-well culture plates treated with 206.8 µmol L^{-1} and 102.7 µmol L^{-1} MED for 48 h, resp. Then cells were collected and fixed by pre-cooled 70 % ethanol overnight at –20 °C. The cells were washed with PBS and stained with 50 µg mL^{-1} RNase A (Solarbio, China) and 0.025 µg propidium iodide (PI) according to the cell cycle assay kit (Solarbio). The cell cycle distribution was measured by flow cytometry FACS Calibur system (BD Biosciences, USA).

Cellular apoptosis assay

The apoptosis of LC cells with MED treatment was determined by Annexin V-FITC/PI double staining. A549 and H157 cells were cultured in 6-well culture plates treated with 206.8 and 102.7 µmol L^{-1} MED for 48 h, and with 290.8 and 125.5 µmol L^{-1} for 24 h, resp. The Annexin V-FITC kit (Beyotime) was used according to the manufacturer's instructions. The cells were washed with PBS, digested, collected, and re-suspended in 195 µL binding buffer. Then, 5 µL Annexin V-FITC and 10 µL PI were added, and the cells were incubated for 20 min at room temperature in the dark. The cells were re-suspended in 300 µL PBS and analyzed using the flow cytometry (see above).

Live and dead cell detection

A549 and H157 cells were cultured in a glass bottom cell culture dish treated with 206.8 µmol L^{-1} and 102.7 µmol L^{-1} MED for 48 h, resp. The Calcein-AM/PI double staining kit (Beyotime) was used according to the manufacturer's instructions. The cells were

washed with PBS and resuspended with an appropriate volume of Calcein-AM working solution. The cells were then stained with PI for 30 min at 37 °C in the darkness. The images were shown by a confocal laser scanning microscope (Leica, Germany), in which live cells were stained by Calcein-AM (green) and dead cells were labeled by PI (red).

Quantitative real-time PCR

To identify the molecular mechanisms of MED against LC, apoptosis-related genes (*caspase-3* (*Casp3*), *caspase-10* (*Casp10*), *BAX*, *Bak1*, *CYCS*) (23-25), anti-apoptotic gene (*Bcl-2*), proliferative genes (*Bid*, *NF-κB*) (26-28) and tumor suppressor gene (*TP53*) (29, 30) were analyzed under the treatment by MED in A549 and H157 cells. Total RNA was extracted from A549 and H157 cells by using the RNAprep pure cell kit (DP430, Tiangen, China), and 1 μg RNA was transcribed to cDNA using FastKing RT kit (KR116-02, Tiangen) following the manufacturer's instructions. PCR master mix was used to carry out the real-time PCR according to the manufacturer's protocols. The primer sequences of *Casp3*, *Casp10*, *Bcl-2*, *BAX*, *Bak1*, *Bid*, *CYCS*, *NF-κB1*, *TP53*, and *GAPDH* were obtained from Tsingke Biotechnology

Table II. Primer sequences for real-time PCR

Gene	Primer	Sequence
Casp3	Forward	5′-CTCGCTCTGGTACGGATGTG-3′
	Reverse	5′-ACTACTTCCCCAGTAAATACCCT-3′
Casp10	Forward	5′-TAGGATTGGTCCCCAACAAGA-3′
	Reverse	5′-GAGAAACCCTTTGTCGGGTGG-3′
Bcl-2	Forward	5′-ATCTCCCTGTTGACGCTCT-3′
	Reverse	5′-CATCTTCTCCTTCCAGCCT-3′
BAX	Forward	5′-CCTTTTGCTTCAGGGTTTCA-3′
	Reverse	5′-GAGAAACCCTTTGTCGGGTGG-3′
Bak1	Forward	5′-TCTGGCCCTACACGTCTACC-3′
	Reverse	5′-ACAAACTGGCCCAACAGAAC-3′
Bid	Forward	5′-ATGGACCGTAGCATCCCTCC-3′
	Reverse	5′-GTAGGTGCGTAGGTTCTGGT-3′
CYCS	Forward	5′-GGTGATGTTGAGAAAGGCAAG-3′
	Reverse	5′-GTTCTTATTGGCGGCTGTGT-3′
NF-κB1	Forward	5′-ACTGTGAGGATGGGATCTGC-3′
	Reverse	5′-CCTTCTGCTTGCAAATAGGC-3′
TP53	Forward	5′-GTTCCGAGAGCTGAATGAGG-3′
	Reverse	5′-TCTGAGTCAGGCCCTTCTGT-3′
GAPDH	Forward	5′-ACCACAGTCCATGCCATCAC-3′
	Reverse	5′-TCCACCACCCTGTTGCTGTA-3′

Co., Ltd. and listed in Table II. Relative gene expression values were obtained using the $2^{-\Delta\Delta CT}$ method and normalized using controls. The primer sequences used in Real-time PCR reactions were as follows in Table II.

Western blot analysis

The cells were lysed by using RIPA buffer (R0010, Solarbio) with 1 mmol L^{-1} phenyl-methylsulfonyl fluoride (PMSF) (P0100, Solarbio). The proteins were collected and concentrations were detected by a BCA protein concentration assay kit (PC0020, Solarbio) according to the manufacturer's instructions. Electrophoresis was performed with sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), and protein was transferred onto polyvinylidene fluoride (PVDF) membranes (Millipore, USA). Then the membranes were blocked in 5 % nonfat milk at room temperature for 1 h, followed by incubating with the appropriate primary antibody at 4 °C overnight. After washing three times in 1×Tris-buffered saline and Tween 20 (TBST) buffer, the secondary antibodies were added and incubated at room temperature for 1 h. The membranes were washed in 1×TBST buffer three times for about half an hour each time. Finally, the proteins were detected by the ECL kit (PE0010, Solarbio). The primary antibodies were as follows: β-actin (1:5000; Cell Signaling Technology, USA), BAX (1:1000; Cell Signaling Technology), Bak1 (1:1000; Cell Signaling Technology), Bcl-2 (1:1000; Cell Signaling Technology), *Casp3* (1:1000; Cell Signaling Technology) and Bid (1:1000; Cell Signaling Technology). The secondary antibodies were as follows: goat anti-mouse IgG (H+L)-horseradish peroxidase (HRP) (1:3000, Tianjin Sungene Biotech Co., Ltd., China), goat anti-rabbit IgG (H+L)-horseradish peroxidase (1:3000, Tianjin Sungene Biotech Co.). Protein bands were analyzed with Image J software. The results of each protein were obtained by detecting three groups of different samples.

Animal experiments

In order to establish a xenograft mouse model, ten female BALB/c nude mice (6 weeks old) were injected with 6×10^6 A549 or 6×10^6 H157 cells subcutaneously into the back of mice. When tumors reached a diameter of 3 to 5 mm, mice were randomly divided into two groups (*n* = 5) and administered intraperitoneally 10 mg kg^{-1} MED or PBS every three days, resp. Tumor size was measured and calculated by the formula: volume = (length × width^2)/2. Finally, tumor-bearing mice injected with A549 or H157 were sacrificed on the 30th day and 15th day, resp. The volume of tumors was recorded.

The animal study was reviewed, approved, and carried out in compliance with the Animal management rules of the China-Japan Friendship Hospital having ethics approval number 2021-42-K26.

Statistical analysis

Statistical analysis was conducted by using GraphPad Prism 5.0 software. Statistical differences were detected by Student's *t*-test between two groups and one-way ANOVA for three or more groups. The experiment was repeated three times, and the statistical results were expressed as mean ± standard deviation (SD). A *p*-value < 0.05 was used as the criterion for statistical significance.

RESULTS AND DISCUSSION

Medicarpin on lung cancer cells proliferation and cell cycle arrest

MED significantly inhibited the proliferation of A549 and H157 cells in a concentration- and time-dependent manner (Figs. 2a and 2b). Furthermore, the half maximal inhibitory concentration (IC_{50}) value of MED on A549 cells at 24 h and 48 h was 290.8 ± 23.2 and 206.8 ± 13.2 µmol L^{-1}, resp., whereas for H157 cells at 24 h and 48 h it was 125.5 ± 9.2 and 102.7 ± 13.2 µmol L^{-1}, resp. These results indicated that MED can inhibit the proliferation of LC cells *in vitro*.

The cell cycle distribution of A549 and H157 cells was analyzed *via* propidium iodide staining. MED affected the cell cycle and increased the proportion of the G2 phase of both

Fig. 2. Effects of medicarpin on proliferation and cell cycle of A549 and H157 cell lines: a) and b) A549 and H157 cell lines proliferation depending on concentration and culture time; c) and d) percentage of G1, S and G2 phase of A549 and H157 cell lines with MED treatment. Data are displayed as mean ± SD of three independent experiments. Statistically significant difference: *$p < 0.05$.

A549 and H157 cells (Figs. 2c,d). There weren't significant differences at G1 and S phasea between DMSO and MED groups.

Medicarpin and apoptosis of lung cancer cells

MED could induce the apoptosis of A549 and H157 cells in a time-dependent manner (Figs. 3a,b). Specifically, the proportion of apoptotic cells was 16.3 ± 4.7 % and 54.7 ± 1.6 % in A549 cells, 21.1 ± 1.8 % and 46.2 ± 5.7 % in H157 cells after 24 and 48 h, resp. Compared to DMSO, MED led to significant cell death of A549 and H157 cells after 24 h (Fig. 3c); the proportion of apoptotic cells induced by MED treatment after 48 h was significantly higher than that after 24 h.

Medicarpin and expression of apoptosis-related genes and proteins

In A549 cells, MED treatment significantly elevated the expression of *Casp3*, *BAX*, *Bak1*, and *NF-κB*, and decreased the expression of *Bcl-2*, *Bid*, and *CYCS* compared to DMSO (Fig. 4a). In H157 cells, MED treatment significantly elevated the expression of *Casp3*, *BAX*, *Bak1*, and *TP53*, and decreased the expression of *Bcl-2*, *Bid*, and *NF-κB* compared to DMSO (Fig. 4b). In both A549 and H157 cells, apoptosis-related genes *Casp3*, *BAX*, and *Bak1* were upregulated, anti-apoptotic gene *Bcl-2* and proliferative gene *Bid* was downregulated. There was no increase in the expression level of *CYCS* either in A549, and H157 cells with MED treatment. This may be attributed to the increase in the expression level of cytoplasmic *CYCS*; RT-PCR only detected whole cells and failed to distinguish cytoplasmic *CYCS* or mitochondrial *CYCS*. Besides, *NF-κB* presented different expression trends in A549 and H157 cells with MED treatment, which may be attributed to the heterogeneity of cell lines.

Western blot analysis indicated that the anti-apoptotic protein Bcl-2 was significantly reduced after MED treatment in both A549 and H157 cells. BAX and Bak1, pro-apoptotic proteins, were upregulated after MED treatment. The high ratio of BAX/Bcl-2 led to cell apoptosis. In our study, BAX/Bcl-2 was remarkably increased after MED treatment. Casp3 is an executive apoptotic protein directly contributing to cell death. Here, we found the expression of cleaved Casp3 was significantly upregulated by MED treatment. Finally, Bid as a proliferative protein was remarkably downregulated after MED treatment (Figs. 4c,d).

Medicarpin and other natural moieties and tumor growth *in vitro and in vivo*

Compared with PBS, MED treatment significantly repressed the tumor growth of A549 cells and reduced the tumor mass of A549 cells *in vivo* (Figs. 5a–c). Similarly, MED treatment significantly repressed the tumor growth of H157 cells and reduced the tumor mass of H157 cells *in vivo* (Figs. 5d,e).

Previous studies have shown that several natural compounds have antitumor effects in lung cancer both *in vitro* and *in vivo*. For instance, lanatoside C (IC_{50} = 56.49 ± 5.3 nmol L^{-1}) (31), tubeimoside-1 (IC_{50} = 12.3 μmol L^{-1}) (32), and lotus leaf flavonoids (IC_{50} = 282.1 ± 9.63 μg mL^{-1}) (33) were utilized in the treatment of lung cancer. As a natural isoflavone compound, MED exhibited antitumor effects in A549 and H157 cell lines in this study, the IC_{50} values were 206.8 ± 13.2 μmol L^{-1} and 102.7 ± 13.2 μmol L^{-1} for 48 h, resp. Similarly, some studies showed that MED has antitumor effects in other cancer types, such as head

Fig. 3. Effects of medicarpin on apoptosis of A549 and H157 cell lines: a) and b) flow cytometry analysis in A549 and H157 cell lines for 24 h and 48 h (stained by Annexin V-FITC/PI, percentage of apoptotic cells is detected by FACS; c) A549 and H157 cell lines stained by Calcein-AM/PI double staining kit and observed with laser confocal microcopy (scale bar 100 µm). Data are displayed as mean ± SD of three independent experiments. Statistically significant difference: $*p < 0.05$, $**p < 0.01$, $***p < 0.001$.

Fig. 4. Expression levels of apoptosis-related genes and proteins with medicarpin treatment: a) and b) *Casp3*, *Casp10*, *Bcl-2*, *BAX*, *Bak1*, *Bid*, *CYCS*, *TP53* and *NF-κB*; c) and d) BAX, Bak1, Bcl-2, Casp3 and Bid. Data are displayed as mean ± SD of three independent experiments. Statistically significant difference: *$p < 0.05$, **$p < 0.01$, ***$p < 0.001$.

and neck squamous cell carcinoma (IC_{50} = 80 μmol L⁻¹) (22), leukemia (IC_{50} = 90 μmol L⁻¹) (20) and bladder cancer (IC_{50} = 79.1 μmol L⁻¹ for EJ-1 and 80.3 μmol L⁻¹ for T24) (16) (Table I).

In addition, the dysfunction of the cell cycle usually causes the abnormal proliferation of cancer cells (34). Here, MED could significantly affect the cell cycle by increasing the proportion of the G2 phase in LC cells. Similarly, lanatoside C could induce cell cycle arrest at the G2/M phase in LC A549 cells (31), breast cancer MCF-7 cells (35), hepatocellular carcinoma HepG2 cells (36), and liver cancer Huh7 cells (37). Furthermore, MED inhibited tumor growth and reduced tumor mass of A549 and H157 *in vivo*. Likewise, MED also inhibited the growth of bladder cancer cell lines T24 and EJ-1 *in vivo*.

Fig. 5. Effects of medicarpin on tumor growth *in vivo* of: a) A549 and H157 cell lines, PBS or MED; b), c), d) and e) tumor volume and mass of A549 (*n* = 5) and H157 formed tumors (*n* = 5). Data are displayed as mean ± SD. Statistically significant difference *vs.* PBS group: **p < 0.01, ***p < 0.001.

Natural compounds induce antitumor effects through a variety of mechanisms including the modulation of cell proliferation, apoptosis, and cell cycle (38). Apoptosis is a highly conservative suicide program of the cells regulated by a series of cellular genes and proteins (39). MED induced apoptosis of LC cells in this study, as shown by the increase in the proportion of apoptotic cells in MED-treated compared to DMSO groups. Furthermore, MED upregulated the expression of pro-apoptotic genes (*BAX*, *Bak1*, and *Casp3*) and downregulated anti-apoptotic gene *Bcl-2* and proliferative gene *Bid*. Subsequently, the apoptotic proteins (BAX, Bak1, and Cleaved Casp3) were upregulated, and the anti-apoptotic protein Bcl-2 and proliferative protein Bid were downregulated. Taken together, MED could suppress the proliferation and induce apoptosis of LC cells *via* activation of mitochondrial-

-mediated intrinsic pathways. Moreover, other studies demonstrated that MED changed the balance of pro- and anti-apoptotic proteins. For example, MED induced leukemia cell apoptosis through the upregulation of pro-apoptotic protein BAX and downregulation of anti-apoptotic protein Bcl-2 (20), which were consistent with our study. MED also decreased the expression of cell viability and cell cycle progression (*PDK1*) and increased tumor--suppressor gene *PTEN* to affect PI3K/AKT signal pathway in head and neck squamous cell carcinoma (22) (Table I).

CONCLUSIONS

In conclusion, this study showed that MED could inhibit cell proliferation and induce cell cycle arrest of A549 and H157 cell lines *in vitro*. Furthermore, MED could suppress tumor growth and decrease the tumor mass of LC cells *in vivo*. In fact, MED could induce cell apoptosis through the mitochondrial-mediated intrinsic apoptosis pathway by upregulating the expression levels of pro-apoptotic genes and proteins (BAX, Bak1, and Casp3) and downregulating the gene and protein expression levels of the anti-apoptotic Bcl-2. The above results indicated that MED may be promising in lung cancer treatment.

In addition to pro-apoptotic mechanisms, MED may suppress the growth of LC cells by the inhibition of nuclear signaling, proteasome pathway, and epigenetic mechanisms, which need further investigation.

REFERENCES

1. H. Sung, J. Ferlay, R. L. Siegel, M. Laversanne, I. Soerjomataram, A. Jemal and F. Bray, Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, *CA Cancer J. Clin.* **71**(3) (2021) 209–249; https://doi.org/10.3322/caac.21660

2. W. D. Travis, E. Brambilla and G. J. Riely, New pathologic classification of lung cancer: relevance for clinical practice and clinical trials, *J. Clin. Oncol.* **31**(8) (2013) 992–1001; https://doi.org/10.1200/jco.2012.46.9270

3. A. T. Fathi and J. R. Brahmer, Chemotherapy for advanced stage non-small cell lung cancer, *Semin. Thorac. Cardiovasc. Surg.* **20**(3) (2008) 210–216; https://doi.org/10.1053/j.semtcvs.2008.09.002

4. A. Díaz-Serrano, P. Gella, E. Jiménez, J. Zugazagoitia and L. Paz-Ares Rodríguez, Targeting EGFR in lung cancer: Current standards and developments, *Drugs* **78**(9) (2018) 893–911; https://doi.org/10.1007/s40265-018-0916-4

5. M. Maemondo, A. Inoue, K. Kobayashi, S. Sugawara, S. Oizumi, H. Isobe, A. Gemma, M. Harada, H. Yoshizawa, I. Kinoshita, Y. Fujita, S. Okinaga, H. Hirano, K. Yoshimori, T. Harada, T. Ogura, M. Ando, H. Miyazawa, T. Tanaka, Y. Saijo, K. Hagiwara, S. Morita and T. Nukiwa, Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR, *N. Engl. J. Med.* **362**(25) (2010) 2380–2388; https://doi.org/10.1056/NEJMoa0909530

6. M. Reck, D. Rodríguez-Abreu, A. G. Robinson, R. Hui, T. Csőszi, A. Fülöp, M. Gottfried, N. Peled, A. Tafreshi, S. Cuffe, M. O'Brien, S. Rao, K. Hotta, M. A. Leiby, G. M. Lubiniecki, Y. Shentu, R. Rangwala and J. R. Brahmer, Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer, *N. Engl. J. Med.* **375**(19) (2016) 1823–1833; https://doi.org/10.1056/NEJMoa1606774

7. J. Xie, J. Liu, H. Liu, S. Liang, M. Lin, Y. Gu, T. Liu, D. Wang, H. Ge and S. L. Mo, The antitumor effect of tanshinone IIA on anti-proliferation and decreasing VEGF/VEGFR2 expression on the human non-small cell lung cancer A549 cell line, *Acta Pharm. Sin. B.* **5**(6) (2015) 554–563; https://doi.org/10.1016/j.apsb.2015.07.008

8. H. Luo, C. T. Vong, H. Chen, Y. Gao, P. Lyu, L. Qiu, M. Zhao, Q. Liu, Z. Cheng, J. Zou, P. Yao, C. Gao, J. Wei, C. O. L. Ung, S. Wang, Z. Zhong and Y. Wang, Naturally occurring anti-cancer compounds: shining from Chinese herbal medicine, *Chin. Med.* **14** (2019) Article ID 48 (58 pages); https://doi.org/10.1186/s13020-019-0270-9

9. M. Kluska and K. Woźniak, Natural polyphenols as modulators of etoposide anti-cancer activity, *Int. J. Mol. Sci.* **22**(12) (2021) Article ID 6602 (16 pages); https://doi.org/10.3390/ijms22126602

10. J. Liang, N. Bi, S. Wu, M. Chen, C. Lv, L. Zhao, A. Shi, W. Jiang, Y. Xu, Z. Zhou, W. Wang, D. Chen, Z. Hui, J. Lv, H. Zhang, Q. Feng, Z. Xiao, X. Wang, L. Liu, T. Zhang, L. Du, W. Chen, Y. Shyr, W. Yin, J. Li, J. He and L. Wang, Etoposide and cisplatin versus paclitaxel and carboplatin with concurrent thoracic radiotherapy in unresectable stage III non-small cell lung cancer: a multicenter randomized phase III trial, *Ann. Oncol.* **28**(4) (2017) 777–783; https://doi.org/10.1093/annonc/mdx009

11. Y. Yoneshima, S. Morita, M. Ando, A. Nakamura, S. Iwasawa, H. Yoshioka, Y. Goto, M. Takeshita, T. Harada, K. Hirano, T. Oguri, M. Kondo, S. Miura, Y. Hosomi, T. Kato, T. Kubo, J. Kishimoto, N. Yamamoto, Y. Nakanishi and I. Okamoto, Phase 3 trial comparing nanoparticle albumin-bound paclitaxel with docetaxel for previously treated advanced NSCLC, *J. Thorac. Oncol.* **16**(9) (2021) 1523–1532; https://doi.org/10.1016/j.jtho.2021.03.027

12. X. Jiang, W. Zhao, F. Zhu, H. Wu, X. Ding, J. Bai, X. Zhang and M. Qian, Ligustilide inhibits the proliferation of non-small cell lung cancer via glycolytic metabolism, *Toxicol. Appl. Pharmacol.* **410** (2021) Article ID 115336 (25 pages); https://doi.org/10.1016/j.taap.2020.115336

13. J. Zou, Y. Yang, Y. Yang and X. Liu, Polydatin suppresses proliferation and metastasis of non-small cell lung cancer cells by inhibiting NLRP3 inflammasome activation via NF-κB pathway, *Biomed. Pharmacother.* **108** (2018) 130–136; https://doi.org/10.1016/j.biopha.2018.09.051

14. A. Ashaq, M. F. Maqbool, A. Maryam, M. Khan, H. A. Shakir, M. Irfan, J. I. Qazi, Y. Li and T. Ma, Hispidulin: A novel natural compound with therapeutic potential against human cancers, *Phytother. Res.* **35**(2) (2021) 771–789; https://doi.org/10.1002/ptr.6862

15. K. S. Prabhu, A. A. Bhat, K. S. Siveen, S. Kuttikrishnan, S. S. Raza, T. Raheed, A. Jochebeth, A. Q. Khan, M. Z. Chawdhery, M. Haris, M. Kulinski, S. Dermime, M. Steinhoff and S. Uddin, Sanguinarine mediated apoptosis in non-small cell lung cancer via generation of reactive oxygen species and suppression of JAK/STAT pathway, *Biomed. Pharmacother.* **144** (2021) Article ID 112358 (11 pages); https://doi.org/10.1016/j.biopha.2021.112358

16. Y. Chen, L. Yin, M. Hao, W. Xu, J. Gao, Y. Sun, Q. Wang, S. Chen, Y. Liang, R. Guo, J. Zhang, J. Li, Q. Zhai, R. Cheng, J. Wang, H. Wang and Z. Yang, Medicarpin induces G1 arrest and mitochondria-mediated intrinsic apoptotic pathway in bladder cancer cells, *Acta Pharm.* **73**(2) (2023) 211–225; https://doi.org/10.2478/acph-2023-0016

17. J. H. Kim, D. M. Kang, Y. J. Cho, J. W. Hyun and M. J. Ahn, Medicarpin increases antioxidant genes by inducing NRF2 transcriptional level in HeLa cells, *Antioxidants* (Basel) **11**(2) (2022) Article ID 421 (10 pages); https://doi.org/10.3390/antiox11020421

18. B. Bhargavan, D. Singh, A. K. Gautam, J. S. Mishra, A. Kumar, A. Goel, M. Dixit, R. Pandey, L. Manickavasagam, S. D. Dwivedi, B. Chakravarti, G. K. Jain, R. Ramachandran, R. Maurya, A. Trivedi, N. Chattopadhyay and S. Sanyal, Medicarpin, a legume phytoalexin, stimulates osteoblast differentiation and promotes peak bone mass achievement in rats: evidence for estrogen receptor β-mediated osteogenic action of medicarpin, *J. Nutr. Biochem.* **23**(1) (2012) 27–38; https://doi.org/10.1016/j.jnutbio.2010.11.002

19. A. M. Tyagi, A. K. Gautam, A. Kumar, K. Srivastava, B. Bhargavan, R. Trivedi, S. Saravanan, D. K. Yadav, N. Singh, C. Pollet, M. Brazier, R. Mentaverri, R. Maurya, N. Chattopadhyay, A. Goel and D. Singh, Medicarpin inhibits osteoclastogenesis and has nonestrogenic bone conserving effect in ovariectomized mice, *Mol. Cell. Endocrinol.* **325**(1–2) (2010) 101–109; https://doi.org/10.1016/j.mce.2010.05.016

20. G. Gatouillat, A. A. Magid, E. Bertin, H. El btaouri, H. Morjani, C. Lavaud and C. Madoulet, Medicarpin and millepurpan, two flavonoids isolated from *Medicago sativa*, induce apoptosis and overcome multidrug resistance in leukemia P388 cells, *Phytomedicine* **22**(13) (2015) 1186–1194; https://doi.org/10.1016/j.phymed.2015.09.005

21. R. Trivedi, R. Maurya and D. P. Mishra, Medicarpin, a legume phytoalexin sensitizes myeloid leukemia cells to TRAIL-induced apoptosis through the induction of DR5 and activation of the ROS-JNK-CHOP pathway, *Cell Death Dis.* **5**(10) (2014) e1465; https://doi.org/10.1038/cddis.2014.429

22. A. K. Yiğin, H. Donmez, M. Hitit, S. Seven, N. Eser, E. Kurar and M. Seven, The effect of medicarpin on PTEN/AKT signal pathway in head and neck squamous cell carcinoma, *J. Cancer Res. Ther.* **18**(1) (2022) 180–184; https://doi.org/10.4103/jcrt.jcrt_641_21

23. A. Mohr, L. Deedigan, S. Jencz, Y. Mehrabadi, L. Houlden, S. M. Albarenque and R. M. Zwacka, Caspase-10: a molecular switch from cell-autonomous apoptosis to communal cell death in response to chemotherapeutic drug treatment, *Cell Death Differ.* **25**(2) (2018) 340–352; https://doi.org/10.1038/cdd.2017.164

24. H. S. Chin, M. X. Li, I. K. L. Tan, R. L. Ninnis, B. Reljic, K. Scicluna, L. F. Dagley, J. J. Sandow, G. L. Kelly, A. L. Samson, S. Chappaz, S. L. Khaw, C. Chang, A. Morokoff, K. Brinkmann, A. Webb, C. Hockings, C. M. Hall, A. J. Kueh, M. T. Ryan, R. M. Kluck, P. Bouillet, M. J. Herold, D. H. D. Gray, D. C. S. Huang, M. F. van Delft and G. Dewson, VDAC2 enables BAX to mediate apoptosis and limit tumor development, *Nat. Commun.* **9**(1) (2018) Article ID 4976 (13 pages); https://doi.org/10.1038/s41467-018-07309-4

25. H. Xian and Y. C. Liou, Loss of MIEF1/MiD51 confers susceptibility to BAX-mediated cell death and PINK1-PRKN-dependent mitophagy, *Autophagy* **15**(12) (2019) 2107–2125; https://doi.org/10.1080/15548627.2019.1596494

26. L. Bai, H. M. Ni, X. Chen, D. DiFrancesca and X. M. Yin, Deletion of Bid impedes cell proliferation and hepatic carcinogenesis, *Am. J. Pathol.* **166**(5) (2005) 1523–1532; https://doi.org/10.1016/s0002-9440(10)62368-1

27. A. Wree, C. D. Johnson, J. Font-Burgada, A. Eguchi, D. Povero, M. Karin and A. E. Feldstein, Hepatocyte-specific Bid depletion reduces tumor development by suppressing inflammation-related compensatory proliferation, *Cell Death Differ.* **22**(12) (2015) 1985–1994; https://doi.org/10.1038/cdd.2015.46

28. M. J. Morgan and Z. G. Liu, Crosstalk of reactive oxygen species and NF-κB signaling, *Cell Res.* **21**(1) (2011) 103–115; https://doi.org/10.1038/cr.2010.178

29. C. Yu, S. Yan, B. Khambu, X. Chen, Z. Dong, J. Luo, G. K. Michalopoulos, S. Wu and X. M. Yin, Gene expression analysis indicates divergent mechanisms in DEN-induced carcinogenesis in wild type and Bid-deficient livers, *PLoS One* **11**(5) (2016) e0155211; https://doi.org/10.1371/journal.pone.0155211

30. S. H. Moon, C. H. Huang, S. L. Houlihan, K. Regunath, W. A. Freed-Pastor, J. P. t. Morris, D. F. Tschaharganeh, E. R. Kastenhuber, A. M. Barsotti, R. Culp-Hill, W. Xue, Y. J. Ho, T. Baslan, X. Li, A. Mayle, E. de Stanchina, L. Zender, D. R. Tong, A. D'Alessandro, S. W. Lowe and C. Prives, p53

represes the mevalonate pathway to mediate tumor suppression, *Cell* **176**(3) (2019) 564–580; https://doi.org/10.1016/j.cell.2018.11.011

31. D. Reddy, R. Kumavath, P. Ghosh and D. Barh, Lanatoside C induces G2/M cell cycle arrest and suppresses cancer cell growth by attenuating MAPK, Wnt, JAK-STAT, and PI3K/AKT/mTOR signaling pathways, *Biomolecules* **9**(12) (2019) Article ID 792 (20 pages); https://doi.org/10.3390/biom9120792

32. W. Hao, S. Wang and Z. Zhou, Tubeimoside-1 (TBMS1) inhibits lung cancer cell growth and induces cells apoptosis through activation of MAPK-JNK pathway, *Int. J. Clin. Exp. Pathol.* **8**(10) (2015) 12075–12083.

33. X. B. Jia, Q. Zhang, L. Xu, W. J. Yao and L. Wei, Lotus leaf flavonoids induce apoptosis of human lung cancer A549 cells through the ROS/p38 MAPK pathway, *Biol. Res.* **54**(1) (2021) Article ID 7 (15 pages); https://doi.org/10.1186/s40659-021-00330-w

34. T. Otto and P. Sicinski, Cell cycle proteins as promising targets in cancer therapy, *Nat. Rev. Cancer* **17**(2) (2017) 93–115; https://doi.org/10.1038/nrc.2016.138

35. Y. Hu, K. Yu, G. Wang, D. Zhang, C. Shi, Y. Ding, D. Hong, D. Zhang, H. He, L. Sun, J. N. Zheng, S. Sun and F. Qian, Lanatoside C inhibits cell proliferation and induces apoptosis through attenuating Wnt/β-catenin/c-Myc signaling pathway in human gastric cancer cell, *Biochem. Pharmacol.* **150** (2018) 280–292; https://doi.org/10.1016/j.bcp.2018.02.023

36. M. Rasheduzzaman, H. Yin and S. Y. Park, Cardiac glycoside sensitized hepatocellular carcinoma cells to TRAIL via ROS generation, p38MAPK, mitochondrial transition, and autophagy mediation, *Mol. Carcinog.* **58**(11) (2019) 2040–2051; https://doi.org/10.1002/mc.23096

37. I. Durmaz, E. B. Guven, T. Ersahin, M. Ozturk, I. Calis and R. Cetin-Atalay, Liver cancer cells are sensitive to lanatoside C induced cell death independent of their PTEN status, *Phytomedicine* **23**(1) (2016) 42–51; https://doi.org/10.1016/j.phymed.2015.11.012

38. A. Rauf, T. Abu-Izneid, A. A. Khalil, M. Imran, Z. A. Shah, T. B. Emran, S. Mitra, Z. Khan, F. A. Alhumaydhi, A. S. M. Aljohani, I. Khan, M. M. Rahman, P. Jeandet and T. A. Gondal, Berberine as a potential anticancer agent: A comprehensive review, *Molecules* **26**(23) (2021) Article ID 7368 (19 pages); https://doi.org/10.3390/molecules26237368+

39. D. Bertheloot, E. Latz and B. S. Franklin, Necroptosis, pyroptosis and apoptosis: an intricate game of cell death, *Cell. Mol. Immunol.* **18**(5) (2021) 1106–1121; https://doi.org/10.1038/s41423-020-00630-3

40. D. E. Hong, J. E. Yu, J. W. Lee, D. J. Son, H. P. Lee, Y. Kim, J. Y. Chang, D. W. Lee, W. K. Lee, J. Yun, S. B. Han, B. Y. Hwang and J. T. Hong, A natural CHI3L1-targeting compound, ebractenoid f, inhibits lung cancer cell growth and migration and induces apoptosis by blocking CHI3L1/AKT signals, *Molecules* **28**(1) (2022) Article ID 329 (16 pages); https://doi.org/10.3390/molecules28010329